Tumor cell – cytotoxic T lymphocyte immune synapse (IS)

The tumor cell – cytotoxic T lymphocyte (CTL) immune synapse is a specialized, highly organized interface formed between a T cell and a target tumor cell (Dieckmann et al., 2016). This structure is essential for the directed secretion of cytotoxic granules, such as perforin and granzymes, which induce apoptosis in the cancer cell (Huppa & Davis, 2003). The synapse is characterized by the spatial organization of receptors and adhesion molecules, including the T-cell receptor (TCR) and LFA-1, into concentric rings known as supramolecular activation clusters (SMACs) (Dustin, 2014). In oncology, this synapse is the primary site where immune checkpoint molecules like PD-1 and PD-L1 interact to inhibit T-cell activity, allowing for immune evasion (Monks et al., 1998). Therapeutic interventions such as checkpoint inhibitors, bispecific T-cell engagers (BiTEs), and CAR-T cell therapies aim to restore or enhance the formation and functionality of this synapse to promote tumor clearance (Dustin, 2014). Understanding the dynamics of the immune synapse is critical for addressing therapeutic resistance and optimizing immunotherapy efficacy.

Other names

Immunological synapseCytotoxic synapseT-cell synapseCTL-tumor synapseSupramolecular activation cluster

Modulation of the immune synapse to enhance or restore T-cell mediated cytotoxicity against tumor cells through checkpoint blockade, T-cell redirection, or synapse stabilization.